Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

S. Doody, Rachelle; G. Thomas, Ronald; R. Farlow, Martin; Iwatsubo, Takeshi; Vellas, Bruno; Joffe, Steven; Kieburtz, Karl; Raman, Rema; Sun, Xiaoying; Aisen, Paul; Siemers, Eric; Liu‐Seifert, Hong; C. Mohs, Richard

doi:10.1056/nejmoa1312889

Public

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

Published in New England Journal of Medicine • Jan 22, 2014

Authors:

Rachelle S. Doody

Ronald G. Thomas

Martin R. Farlow

Abstract

BACKGROUND: Alzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss. Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain. METHODS: In two...

Subject

Medicine

Placebo

Alzheimer's disease

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!